iCare, a subsidiary of Revenio Group, announced today the launch of iCare IC1000™, the next-generation handheld tonometer built on the proven iCare rebound tonometry platform and designed to bring guided operation to handheld IOP measurement in modern clinical settings.

iCare IC1000 combines reliable IOP measurement with GuideCam™ alignment, anesthesia-free operation and digital data transfer capabilities to support confident and efficient use across eye care environments.

Designed to deliver repeatable IOP measurements, iCare IC1000 simplifies daily tonometry routines for clinicians and patients alike. By combining guided alignment, fast acquisition and the established benefits of iCare rebound technology, it helps reduce operator dependency, support efficient clinical workflows and improve the patient experience.

“iCare IC1000 brings the iCare experience to the next generation of handheld tonometry,” said Daniele Mantovano, iCare’s Product Marketing Director. “By combining trusted rebound technology with guided alignment, patient comfort and digital workflow capabilities, we are giving eye care practitioners a simpler and more efficient way to acquire reliable IOP measurements in everyday clinical practice.”

iCare IC1000 features an intuitive user interface and an easy-to-follow workflow. GuideCam alignment supports positioning and measurement acquisition, helping operators perform IOP measurements with greater confidence and consistency. The guided workflow is designed to reduce operator dependency and make adoption easier for new or rotating staff.

Built for busy clinical environments, iCare IC1000 supports efficient measurement acquisition also in demanding cases. Quick Measure enables faster IOP acquisition when needed, while anesthesia-free operation and single-use probes help reduce procedural burden, support hygiene management and improve patient comfort.

iCare IC1000 retains the unique advantages of rebound tonometry that have made iCare a global leader in ophthalmic tonometry:

• No need for topical anesthesia or fluorescein dye.
• No need for calibration procedures.
• No need for probe disinfection or sterilization, thanks to single-use probes.

With iCare IC1000, iCare also introduces SmartCradle™ as an important element supporting a more connected tonometry workflow. SmartCradle keeps the device charged between uses and supports digital transfer of IOP measurement data, helping reduce manual steps and connect tonometry results to clinical workflows where available.

iCare IC1000 Fact box:

GuideCam alignment
GuideCam provides visual guidance during alignment, helping the operator position the device correctly for easier, faster and more consistent IOP acquisition.

SmartCradle
SmartCradle is designed to support charging, connectivity and digital transfer of IOP measurement data, helping connect tonometry results to clinical workflows where available.

Anesthesia-free rebound tonometry
Based on iCare’s proven rebound technology, iCare IC1000 enables comfortable IOP measurement without topical anesthesia or fluorescein dye, supporting a smoother experience for both clinicians and patients.

www.icare-world.com/product/icare-ic1000-tonometer/
Availability varies by market. iCare IC1000 is not available for sale in the United States. FDA review is ongoing.

For further information, please contact
Daniele Mantovano, Product Marketing Director
tel. +39 346 100 8040
daniele.mantovano@icare-world.com

Distribution
Main media
www.reveniogroup.fi/en

Revenio Group in brief
Revenio is a leading turnkey solutions provider in the global eye care market. The Group provides fast, easy-to-use and reliable tools for the diagnosis of a wide range of eye diseases. Under the iCare and Visionix brands, Revenio’s solutions include, among others, tonometers, retinal imaging devices, optical coherence tomography (OCT), perimeters, multimodal diagnostic platforms, refraction systems and software solutions.

In May 2026, Revenio joined forces with Visionix, creating the industry’s most innovative, creative and comprehensive entity serving eye care professionals across optometry, optical retail and ophthalmology. In 2025, Revenio Group’s net sales amounted to EUR 109.7 million and operating profit totaled EUR 25.4 million. Revenio Group Corporation is listed on Nasdaq Helsinki Ltd with the trading symbol REG1V.